Member Info for Epsilon

Free advertising for Microsalt surely?

https://www.bbc.co.uk/news/articles/c4g4l54g2ppo

...[your]

I feel you're pain. Try the Ghostery extension on your browser. Similar extensions are also available. It cleared all the garbage that you're describing, for me at least. In addition, you might want to change your browser cookie settings to a more strict/secure setting to help with those pesky tracking cookies.

Having criminal convictions does not preclude one from holding directorships, unless it's related to financial crime. However, when the criminal conviction is concerning organised crime then I do think there a remote possibility of reputational risk in the commercial sphere. I have no interest in the share price of Haydale one way or the other.

Thanks for the correction. However, in the grand scheme the actual % is pretty irrelevant when compared to my main argument, which is to run the search.

Okay, so if you need some more help; the current Major Shareholders of Haydale include:

Quidos Technologies at 16.21%. This is controlled by Quidos Holdings Ltd.

Nicholas Simon Pritchard 9.9%. He is a director of both Quidos Technologies and its ultimate owner, Quidos Holdings (which he controls).

Simon Turek 7.94% is a director of Quidos Technologies and CEO of Haydale.

So add these up and you get 34.05% of Haydale shares. All very nice.

Lets go a bit deeper; Nicholas Pritchard has interests/directorships in several other businesses around Bangor, including a football club. This is public knowledge.

So what happens when one does a Google search with the terms, "Nicholas Pritchard Bangor"? I'll let you do that...

I should have been a fisherman...I've been trawling back to 2010. Hint.

Run a search on Quidos Technologies' directors.

I'm gone.

Hi,

You'll be pleased to know that your share holdings do not evaporate if the company goes private. It's your slice of the company and that's on file.

Shareholders (you) are recorded on the Shareholder Registry at

https://www.computershare.com/uk , and it is this company that is organising the proxy voting for the AGM. I think there are about 400 shareholders...some may have passed away of course!

You may be able to log in, after some effort, and cast your vote on the various Resolutions put forward via your computer. It may be possible to talk with them over the phone to explain your situation and I'm sure they'll help you with the logistics. Perhaps you may have moved house since buying shares so they may have sent stuff to the wrong house? Also take a look at the News section of the Reneuron website for information on the AGM Resolutions:

https://www.reneuron.com/wp-content/uploads/2025/11/ReNeuron-Group-plc-Circular-and-AGM-Notice.pdf

My guess is that shares will be able to be traded on a specialised platform if the Reneuron goes private. The Chairman has done this a few times with de-listed AIM companies - most, if not all, seem to have ended up on the JP Jenkins platform. https://www.jpjenkins.com/ . The website explains how to go about buying/selling the shares in their list of private/ de-listed companies.

I've no idea, unfortunately. I just hope Reneuron can get through the current biotech bloodbath.

Looks like the burn rate was just too high for this exosome company for it to survive current market conditions. Assets up for sale.
https://www.fiercebiotech.com/biotech/codiak-biosciences-files-bankruptcy-after-unable-satisfy-financial-needs

I note the previous leading major shareholder Richard Griffiths got rinsed care of WANdisco, which has just been suspended due to 'potential fraud'. Unfortunately he owns 5.3% of that outfit; his holding was worth over £50M yesterday...and now....er...10?...0?

...College, London.

They used Reneuron's hippocampal progenitor/stem cell line in the study, suggesting that King's is one of Reneuron's academic partners.

"Researchers predict Alzheimer's progression 3.5 years early with unique blood test"
https://www.fiercebiotech.com/medtech/researchers-predict-alzheimers-progression-35-years-early-unique-blood-test

This work was based at King's C

Looks like Mr Ross is shuffling his priorities around at the expense /relief (depending on your view) of Bivictrix:

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company" or the "Group")

Board Change

Dr. Michael Kauffman, M.D., Ph.D. appointed as Non-Executive Chairman

Iain Ross to remain a Board member

Alderley Park, 6 January 2023 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces that Dr. Michael Kauffman, M.D., Ph.D. has been appointed as Non-Executive Chairman. Dr Kauffman takes over from Iain Ross, who will continue as a Non-Executive Director on the BiVictriX Board, but steps down as Chairman due to other work commitments.

Prior to becoming Non-Executive Chairman, Dr. Kauffman was appointed as Non-Executive Director of BiVictriX in January 2022. He is a highly experienced cancer drug developer, having been instrumental in the approval of several oncology therapeutics over twenty years of working across preclinical research, clinical development, regulatory strategy and commercialisation. As Non-Executive Chairman, he will draw upon his previous experience as Co-Founder and Chief Executive Officer of oncology company Karyopharm Therapeutics Inc., which he guided from a discovery stage biotechnology company to a commercial stage organisation, with global approvals of XPOVIO®. He also led the Kyprolis® development programme at Proteolix and then Onyx Pharmaceuticals, the Velcade® development programme at Millennium Pharmaceuticals, and has held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr Kauffman currently holds other Non-Executive Board positions at Verastem Oncology, Adicet Bio and Kezar Life Sciences.

Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc, commented: "With the recent identification of our lead candidate, the transition of Michael Kauffman to Non-Executive Chairman of the Board comes at a pivotal time in BiVictriX's development. I am delighted to welcome Michael to his new role; no doubt his wealth of expertise across oncology drug development will continue to prove invaluable during the next stage of our progression. I would like to also express gratitude on behalf of the whole Company to Iain for his excellent support, taking us through from IPO to candidate identification and look forward to continuing to work alongside him as a valued member of our Board."

https://www.allenbycapital.com/client/reneuron-plc/

The slides from the recent conference which are mentioned in the report are now on Reneuron's website : https://www.reneuron.com/presentations-list/extracellular-vesicle-based-therapeutic-development-summit-october-2022/

https://www.allenbycapital.com/client/reneuron-plc/

Published today. The report gives Rene a valuation of £41m or 72p per share with some assumptions/caveats. This is 37% higher than their last report in July (different author though).

https://www.science.org/doi/10.1126/sciadv.abj7002

I would love to know what this "Rod-derived Cone Viability Factor" (that is released by the rod cells) JCyte has identified actually is. Can it be chemically synthesised, or can it be produced in bulk via ReNeuron's immortalised stem cell line for example? And does it need to be transported via exosomes, or could a simple injection suffice?

My hunch is the mechanism of action for both JCyte's and Renuron's cell lines is the same/similar, it's just the techniques that are different. If I was a big pharma boss I would buy both companies just to hedge my bets!